The Management of Ocular Surface Squamous Neoplasia (OSSN)
2022
Clarice H. Y. Yeoh | Jerome J. R. Lee | Blanche X. H. Lim | Gangadhara Sundar | Jodhbir S. Mehta | Anita S. Y. Chan | Dawn K. A. Lim | Stephanie L. Watson | Santosh G. Honavar | Ray Manotosh | Chris H. L. Lim
The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensus regarding the best way to manage OSSN with no existing guidelines to date. This paper seeks to evaluate evidence surrounding available treatment modalities and proposes an approach to management. The approach will guide ophthalmologists in selecting the most appropriate treatment regime based on patient and disease factors to minimize treatment related morbidity and improve OSSN control. Further work can be done to validate this algorithm and to develop formal guidelines to direct the management of OSSN.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
